Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Hepatocellular Carcinoma | Correction

Correction to: Three novel circRNAs upregulated in tissue and plasma from hepatocellular carcinoma patients and their regulatory network

Authors: Lianghai Wang, Lisha Zhou, Jun Hou, Jin Meng, Ke Lin, Xiangwei Wu, Xueling Chen

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Excerpt

Following publication of the original article [1], we were notified that Figs. 4 to 7 were misplaced: Fig. 4 in the online version should have been Fig. 5, Fig. 5 in the online version should have been Fig. 6, Fig. 6 in the online version should have been Fig. 7, and Fig. 7 in the online version should have been Fig. 4. Figure citations and figure legends were published in the correct order. …
Literature
1.
Metadata
Title
Correction to: Three novel circRNAs upregulated in tissue and plasma from hepatocellular carcinoma patients and their regulatory network
Authors
Lianghai Wang
Lisha Zhou
Jun Hou
Jin Meng
Ke Lin
Xiangwei Wu
Xueling Chen
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-01788-0

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Primary research

LPCAT1 overexpression promotes the progression of hepatocellular carcinoma

Review

High temperature requirement A1 in cancer: biomarker and therapeutic target

Primary research

Knockdown of circRNA_0007534 suppresses the tumorigenesis of cervical cancer via miR-206/GREM1 axis

Review

Cytotoxicity of synthetic derivatives against breast cancer and multi-drug resistant breast cancer cell lines: a literature-based perspective study

Primary research

Absence of EpCAM in cervical cancer cells is involved in slug induced epithelial-mesenchymal transition

Primary research

Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits